Search Results - "Krempl, G.A."

Neoadjuvant QUAD Shot as Temporizing Measure Prior to Definitive Surgery for Locally Advanced Oral Cavity Cancer by Truong, M.L., Hsieh, M.L., Henson, C., Krempl, G.A.

“…The mainstay of treatment for oral cavity cancer is surgery, often with adjuvant therapies if necessary. However, given issues involving prolonged workup or…”
Get full text

Use of Post-Operative External Beam Radiation Therapy in Patients with Differentiated Thyroid Cancer by Brown, A., Kellogg, A., Mirza, Z., Sears, T., Krempl, G.A., Henson, C.

Get full text

Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx by Gharzai, L.A., Morris, E., Nguyen-Tan, P.F., Rosenthal, D.I., Gillison, M., Harari, P.M., Garden, A.S., Zanotti, K., Caudell, J.J., Jones, C.U., Mitchell, D.L., Krempl, G.A., Ridge, J.A., Gensheimer, M.F., Bonner, J.A., Le, Q.T., Torres-Saavedra, P., Mierzwa, M.L., Schipper, M.

“…The increased incidence of HPV-related cancers has motivated efforts to optimize treatment paradigms for these excellent-prognosis patients. Validation of…”
Get full text

The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer in NRG/RTOG 1016 by Weidhaas, J.B., Harris, J., Gillison, M., Blakaj, D.M., Krempl, G.A., Higgins, K.A., Phan, J., Dunlap, N.E., Mahmood, S., Dorth, J.A., Caudell, J.J., Desai, A.B., Galloway, T.J., Pennington, J.D.D., Zhou, Z., Lathrop, J., Torres-Saavedra, P., Hayes, D.N., Yom, S.S., Le, Q.T.

“…NRG/RTOG 1016 was a non-inferiority phase III trial comparing radiation with cisplatin versus cetuximab monotherapy for patients with HPV-positive…”
Get full text

655MO Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016 by Ringash, J., DeMora, L., Gillison, M.L., Adelstein, D.J., Harari, P., Sturgis, E.M., Basch, E.M., Koyfman, S.A., Krempl, G.A., Blakaj, D.M., Bates, J.E., Galloway, T., Jones, C.U., Beadle, B.M., Torres-Saavedra, P., Le, Q-T., Movsas, B.

Get full text

Hearing Outcomes in Cisplatin or Cetuximab Combined with Radiation for Patients with HPV-Associated Oropharyngeal Cancer in NRG/RTOG 1016 by Runge, C.L., Lyness, J., Gillison, M., Adelstein, D.J., Harari, P.M., Ringash, J.G., Geiger, J.L., Krempl, G.A., Blakaj, D., Bates, J., Galloway, T.J., Jones, C.U., Gensheimer, M., Dunlap, N.E., Phan, J., Caudell, J., Pennington, D., Torres-Saavedra, P., Yom, S.S., Le, Q.T., Movsas, B.

“…NRG/RTOG 1016 was a noninferiority phase 3 trial comparing the efficacy of radiation with either cisplatin (RT+Cisp) or cetuximab (RT+Cetux) for patients with…”
Get full text